Analyses of cytokine gene expression and fecal microbiota in a patient with Cronkhite‐Canada syndrome successfully treated with prednisolone — Hajime Honjo (2023) | RDL Network
Analyses of cytokine gene expression and fecal microbiota in a patient with Cronkhite‐Canada syndrome successfully treated with prednisolone
Article 2023 en
Authors
HH
Hajime Honjo
YM
Yasuhiro Masuta
YO
Yasuo Otsuka
Abstract
1 min read
Although prednisolone treatment is effective in Cronkhite-Canada syndrome (CCS), its mechanisms of action are poorly understood. We performed analyses of cytokine expression and fecal microbiota in a patient with the concurrent occurrence of CCS and rectal cancer, in whom regression of polyposis was achieved by prednisolone. Regression of CCS polyps was accompanied by downregulation of proinflammatory cytokine expression and alterations in microbiota composition; a decrease in <i>Bacteroides fragilis</i> and <i>Peptostreptococcus anaerobius</i> with the promotion of inflammation. We could not completely exclude the possibility that alterations in fecal microbiota composition might be influenced by the presence of advanced cancer. However, this case suggests that the administration of PSL might lead to the regression of CCS polyps through alterations in gut microbiota composition and suppression of proinflammatory cytokine responses.
Alessandro Atzeni, Stephanie Nishi, Nancy Babió, Clara Belzer, Prokopis Konstanti, Jesús Vioqué, Dolores Corella, Olga Castañer, Josép Vidal, Isabel Moreno‐Indias, Laura Torres‐Collado, Eva M. Asensio, Montserrat Fitó, Ana María Gómez‐Pérez, Alejandro Arias, Miguel Ruiz‐Canela, Frank B Hu, Francisco J. Tinahones, Jordi Salas‐Salvadó
Alessandro Atzeni, Stephanie Nishi, Nancy Babió, Clara Belzer, Prokopis Konstanti, Jesús Vioqué, Dolores Corella, Olga Castañer, Josép Vidal, Isabel Moreno‐Indias, Laura Torres‐Collado, Eva M. Asensio, Montserrat Fitó, Ana María Gómez‐Pérez, Alejandro Arias, Miguel Ruiz‐Canela, Frank B Hu, Francisco J. Tinahones, Jordi Salas‐Salvadó
Discussion(0)
No comments yet. Be the first to comment.